Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 2/20 | 0.32 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1067509 | 1.00 | IDO1 (0.34) | IDO1CA1CA2SLC1A1LTA4H | |
| SCHEMBL30980082 | 1.00 | IDO1 (0.34) | IDO1CA1CA2SLC1A1LTA4H | |
| SCHEMBL1067514 | 1.00 | IDO1 (0.34) | IDO1CA1CA2SLC1A1LTA4H | |
| SCHEMBL3616995 | 0.83 | BTN3A1 (0.32) | CA1CA2BTN3A1KIF11 | |
| SCHEMBL2763848 | 0.83 | BTN3A1 (0.32) | CA1CA2BTN3A1KIF11 | |
| SCHEMBL490891 | 0.83 | NOS3 (0.41) | SLC1A1 | |
| SCHEMBL10679170 | 0.83 | BTN3A1 (0.32) | CA1CA2BTN3A1KIF11 | |
| SCHEMBL191235 | 0.83 | NOS3 (0.41) | SLC1A1 | |
| SCHEMBL191236 | 0.83 | NOS3 (0.41) | SLC1A1 | |
| SCHEMBL734855 | 0.81 | CA1 (0.33) | CA1CA2BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669242-B2 | Clostridium difficile toxin inhibitors | Venenum Biodesign, LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | Venenum Biodesign, LLC (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2017214359-A1 | NOVEL CLOSTRIDIUM DIFFICILE TOXIN INHIBITORS | VENENUM BIODESIGN LLC (US) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | GABRA5, GABRA1, GABRA4 | IDO1 390/4885CA1 292/4885CA2 239/4885 |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | GABRA5, GABRA1, GABBR2 | IDO1 368/4885CA1 177/4885CA2 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.